Next Article in Journal
Predicting Acute Kidney Injury after Cardiac Surgery by Machine Learning Approaches
Next Article in Special Issue
Approach to Pulmonary Arteriovenous Malformations: A Comprehensive Update
Previous Article in Journal
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Previous Article in Special Issue
Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia: Real-World Data from the Gemelli Hospital HHT Registry

Review of Pharmacological Strategies with Repurposed Drugs for Hereditary Hemorrhagic Telangiectasia Related Bleeding

Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), 9 Ramiro de Maeztu Street, 28040 Madrid, Spain
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Institute of Health Carlos III, 28040 Madrid, Spain
Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, 300 George Street, New Haven, CT 06511, USA
Author to whom correspondence should be addressed.
J. Clin. Med. 2020, 9(6), 1766;
Received: 24 April 2020 / Revised: 28 May 2020 / Accepted: 3 June 2020 / Published: 6 June 2020


The diagnosis of hereditary hemorrhagic telangiectasia (HHT) is based on the Curaçao criteria: epistaxis, telangiectases, arteriovenous malformations in internal organs, and family history. Genetically speaking, more than 90% of HHT patients show mutations in ENG or ACVRL1/ALK1 genes, both belonging to the TGF-β/BMP9 signaling pathway. Despite clear knowledge of the symptoms and genes of the disease, we still lack a definite cure for HHT, having just palliative measures and pharmacological trials. Among the former, two strategies are: intervention at “ground zero” to minimize by iron and blood transfusions in order to counteract anemia. Among the later, along the last 15 years, three different strategies have been tested: (1) To favor coagulation with antifibrinolytic agents (tranexamic acid); (2) to increase transcription of ENG and ALK1 with specific estrogen-receptor modulators (bazedoxifene or raloxifene), antioxidants (N-acetylcysteine, resveratrol), or immunosuppressants (tacrolimus); and (3) to impair the abnormal angiogenic process with antibodies (bevacizumab) or blocking drugs like etamsylate, and propranolol. This manuscript reviews the main strategies and sums up the clinical trials developed with drugs alleviating HHT.
Keywords: HHT; ALK1; endoglin; raloxifene; bazedoxifene; tranexamic acid; propranolol; FK506; etamsylate; N-acetylcysteine HHT; ALK1; endoglin; raloxifene; bazedoxifene; tranexamic acid; propranolol; FK506; etamsylate; N-acetylcysteine

1. Introduction

Hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber syndrome is a genetic dominant autosomal multisystemic vascular disease, whose penetrance increases with age. The Curaçao criteria were designed to diagnose HHT, and include its clinical symptoms which are spontaneous and recurrent epistaxis (nose bleeds), mucocutaneous telangiectases, visceral localization (gastrointestinal telangiectases and/or arteriovenous malformations (AVMs), mainly in lung, brain or liver), and a first degree family member with a definite diagnosis of HHT (Figure 1A) [1,2,3]. The prevalence of HHT varies between 1:5000 and 1:8000 on average, although because of the “founder effect” and “insulation effect,” the prevalence is higher in some regions such as the Jura region in France, Funen Island in Denmark and the Caribbean Dutch Antilles [3,4,5]. Heterozygous mutations in either ENDOGLIN (ENG) or ACVRL1/ALK1 genes trigger the pathogenesis of HHT in over 90% of HHT patients [6,7]. Less common mutations, responsible for 2% of HHT cases, appear in the SMAD4 gene, leading to a combined syndrome of Juvenile Polyposis HHT (JPHT) [8] consisting of HHT symptoms, colon polyps and thoracic aneurysms [9]. Furthermore, chromosomes 5 and 7 have been described to possess two loci with unknown genes, that cause HHT3 [10] and HHT4, respectively [11]. An HHT-like syndrome called HHT5 has been linked to mutations in BMP9 [12]. All mutations leading to HHT are found in genes belonging to the family of BMP9/TGF-β signaling pathway (Figure 1B).
Moreover, the capillary malformation (CM)/AVM syndrome is phenotypically similar to HHT, and is characterized by the appearance of multiple CMs that are small and red, round to oval shaped with a peripheral white halo and randomly distributed. These are linked to heterozygous pathogenic variants in EPHB4 or RASA1 identified by molecular genetic testing [13].
This review will focus on the pharmacological treatment for bleeding in HHT patients. With 93% of patients suffering light to moderate bleedings, epistaxis presents as the most frequent clinical manifestation of HHT [14,15]. It affects over 90% of patients before the age of 21, normally interfering with their quality of life [16]. Epistaxis are due to the telangiectases of the nasal mucosa, focally dilated venules, often connected directly with dilated arterioles [17]. Directly related to epistaxis is gastrointestinal (GI) bleeding, because of telangiectases in the digestive tract and observed in up to 80% of HHT patients [18]. However, GI bleeding becomes more frequent with age [19]. Although currently there is no optimal available treatment for either epistaxis or GI bleeding, the systemic pharmacological treatments that are used for epistaxis might also be useful to manage GI bleedings.
The pharmaceutical therapies which that are discussed in the following sections address therapies wherein the disease is due to heterozygous germ-line mutations in all cells of the HHT patient. These therapies may not be effective for some cutaneous telangiectases, wherein endothelial cells (EC) may have homozygous mutants for ALK1/ENG according to a recent publication of Snellings et al. [20].

2. General Care and Control of Anemia

To prevent crusting and allow the nasal mucosa to be correctly hydrated in HHT patients, local moisturizing treatments such as humidification, nasal cleaning with a saline solution and lipid-based topical ointments are used [18]. Despite these options, it is challenging to completely avoid nasal or GI bleeding in HHT, often leading to iron deficiency and anemia in these patients. For this reason, the first line treatment of HHT is focused on managing the anemia resulting from bleeding. Iron-enriched diets and iron supplements are cost-effective steps that significantly reduce the need of blood transfusions although the latter may be necessary in severely affected patients [2,21].

3. Therapeutic Pathways/Strategies of Pharmacological Treatments for HHT

The following section focuses on reviewing the pharmacological treatments, from a preclinical perspective. Robert et al. have also recently reviewed this topic [22].
Options to control nose and GI bleeding could be used, according to the following strategies (Table 1). It should be commented that the drugs were included into each group, according to the main mechanism observed in vitro and/or in vivo experiments, yet in some cases other additional mechanisms maybe contributing to the therapeutic effect.
Strategy 1. Although HHT does not result from a clotting failure, the use of antifibrinolytics to restore the balance between coagulation versus fibrinolysis would help to promote a quicker coagulation and to stabilize the fibrin network. Among the antifibrinolytics used for epistaxis treatment, tranexamic acid (TA) and ε-aminocaproic acid (AC) stand out [23,24].
Strategy 2. HHT is associated with haploinsufficiency in ENG or ALK1 genes, therefore stimulating their protein expression is thought to revert the HHT phenotype. At this point, raloxifene hydrochloride and bazedoxifene acetate, two specific estrogen receptor modulators (SERMs), have proven efficiency and safety, and have been designated as orphan drugs for HHT (2010 EU/3/10/730 and 2014 EU/3/14/1367; respectively) [25,26].
Strategy 3. Antiangiogenic therapies tackle the excess of abnormal vasculature present on the nasal mucosa in HHT. Therefore, bevacizumab (BZ) (Avastin®), a humanized monoclonal antibody against the main angiogenic factor, the vascular endothelial growth factor (VEGF), has been widely used and tested on HHT. Its systemic administration has improved hepatic function, delaying the liver transplant [27] but it has not shown consistent results when tested to decrease epistaxis events by topical spray administration [28,29].
Following the same antiangiogenic strategy, pazopanib, thalidomide, and more recently pomalidomide, have been used to inhibit the VEGF pathway.
Similarly, other cardiovascular drugs such as propranolol and timolol (non-specific β-blockers) have shown their benefits in nose bleeding when administered topically (both) and systemically (propranolol) [30] in HHT patients. Recently, the use of the fibroblast growth factor receptor (FGFR) blocker etamsylate, by local spray administration has been proven effective and has been designated as orphan drug for HHT in 2018 (EU/3/18/2087) [31].
Table 2 and Table 3, respectively, summarize the ongoing and finished clinical trials, conducted in HHT with the different drugs, most of them mentioned in this review. In addition, some other recent candidates like Vitamin D, itraconazole and doxycyclin are in ongoing clinical trials.
All the above-mentioned drugs used were repurposed medicines, which have the added value of an immediate use in clinical trials since their safety is already confirmed from their first indication. As stated by Masoudi et al. (2020) [43], “Drug repurposing is a powerful strategy in the discovery scope because of the time and cost savings”. Furthermore, it is an appropriate method for finding therapies for orphan and rare diseases.

3.1. Strategy 1. Antifibrinolysis: ε-Aminocaproic and Tranexamic Acids

Antifibrinolytics block the plasminogen to plasmin conversion by inhibition of its enzymatic disaggregation and consequently, stabilization of the fibrin clot. Accordingly, these drugs are expected to target the wall of the telangiectases where fibrinolysis is activated [44,45].
TA and AC are antifibrinolytic agents used for HHT epistaxis. Both may be administered topically (with the agent embedded in gauze) or systemically by oral intake (500 mg/8 h or even up to 2 g/day) or intravenous administration. AC was the first antifibrinolytic used but showed thrombosis as a side effect and is therefore not recommended in patients prone to thrombosis [46,47,48,49]. In addition, TA has shown longer half-life and higher potency (10-fold) than AC [23,24].
In addition to several case reports with successful results, a study with a total of 14 patients with low risk of thrombosis and for whom their quality of life was poor due to epistaxis, were selected to take TA (500 mg/8 h) orally. TA treatment showed a decrease of nose bleedings and increase of hemoglobin levels in all patients, almost avoiding the transfusion necessity, indicating an overall improvement and no side effects of TA treatment [24]. Although the study was not a formal clinical trial, TA was safe and effective at the doses applied. To highlight, TA administered up to 3 g/day was successful in controlling a massive and life-threatening hemorrhage in an HHT patient [23]. Moreover, some published data from in vitro experiments demonstrated on ECs that TA led to increased mRNA and protein levels of endoglin and ALK1, and improved endothelial functions as tubulogenesis and migration [24]. Thus, elevated endoglin or ALK1 expression may act concomitantly to the main antifibrinolytic action, although the proposed mechanism is only based on in vitro evidence.
Nevertheless, some concern must be taken in HHT patients with the elevated levels of the coagulation protein factor VIII (FVIII) and factor V Leiden, since some reports show an HHT-related increment of these protein levels that favor thrombotic risk in these patients. Another putative risk factor is the presence of high levels of factor V Leiden. Therefore, personalized risk-benefit considerations are demanded for HHT management [50].
Generally, clotting factors levels are not altered in HHT patients (excluding patients with altered factor V or VIII expression). However, one way of shortening the time and frequency of bleeding is by displacing the balance between coagulation and anticoagulation process toward a more quick and stable clotting when the abnormal vessels (mucosa telangiectases) break. This is enhanced by the antifibrinolytics, which prompt the clotting and delay its fibrinolysis. Moreover, telangiectases have been reported to have high fibrinolytic activity by Sabbà et al. [51].
In addition, two clinical trials were performed in HHT centers to assess the benefits of TA in HHT patients with reports published in 2014. In the French ATERO assay, TA was shown effective in a multinational center study [34], while Geisthoff et al. [32], demonstrated efficacy in a double-blind clinical trial phase III-B. However, while TA has demonstrated efficiency by systemic use, when topically used by a nasal spray, it did not significantly decrease nose bleeds when compared to placebo in a clinical trial (NOSE study) conducted by Cure HHT in 2016 [28].

3.2. Strategy 2. Upregulating ENG and ACVRL1

3.2.1. Hormonal Therapy: Specific Estrogen Receptor Modulators (SERMs)

The incidence of epistaxis has been observed to be increased in women after they have reached menopausal age, suggesting that estrogens might play a protective role in HHT-derived bleeding in women. Post-menopausal women are also affected by osteoporosis, the imbalance in the rate of bone remodeling/resorption that predisposes elders to higher chances of bone fracture. NFκB, RANK and its ligand RANKL, as well as osteoprotegerin (OPG) play major roles in this pathogenesis [52] (Figure 2). Based on the observation that pre-menopausal HHT women had fewer epistaxis, a study developed by the Yale University’s Vascular Malformation Centre attempted to treat GI bleeding of 40 transfusion-dependent HHT patients, with a mean age of 57 years, by means of estradiol treatment. Men, to avoid estradiol feminizing effects, were also treated with ethinylestradiol/norethindrone and danazol. The results were satisfactory as most of the 40 patients showed an improvement in hemoglobin levels and needed fewer blood transfusions [53].
The use of hormones to treat HHT-induced bleedings was published later in the form of case reports, but mostly without controls [55]. The main conclusion obtained from these studies was that estrogen-progesterone administered at the doses typically used for oral contraception might reduce bleedings in symptomatic HHT women, becoming a reasonable option for fertile HHT female patients. Zacharski et al. published in 2001 a case report in which the use of tamoxifen had ceased epistaxis in the long term in a post-menopausal patient, concluding for the first time that SERM was properly used to treat epistaxis in an HHT patient [56]. According to this, tamoxifen was used in two clinical trials where it again successfully decreased epistaxis. The first of these two consisted of a placebo controlled clinical trial that included both men and women, while the second comprised a long-term monitored clinical trial in which patients were administered 20 mg tamoxifen [33,54].
In the line of using SERMs to decrease HHT-related bleedings, the safety and efficiency of raloxifene hydrochloride was tested by a Spanish HHT reference unit IDIVAL (Sierrallana/Valdecilla). Raloxifene hydrochloride shows similarities with tamoxifen, also presenting beneficial effects on bone mineralization and on prevention of cardiovascular and gynecological cancer. This study included 19 post-menopausal women, previously diagnosed with osteoporosis, and compared the amount of bleeding before and after 6 months of treatment (no placebo was included in the study). Oral intake of raloxifene (60 mg/day) showed a significant reduction in both the frequency and the amount of epistaxis after 6 months of treatment, also revealing an increase in hemoglobin levels [25]. Raloxifene has been shown to be a transcriptional activator of ENG and ACVRL1/ALK1 promoters, binding to their proximal regions and subsequently increasing these genes’ transcription rate in a context of in vitro experiments on ECs [25]. As a consequence, the protein levels of endoglin and ALK1 increased, thus compensating partially the haploinsufficiency suffered by HHT patients in this study [25]. In 2010, these studies resulted in the European Medicine Agency (EMA) and Food and Drug Administration (FDA) designation of raloxifene hydrochloride as the first orphan drug to treat bleedings in HHT patients (EU/3/10/730). Bazedoxifene acetate, another SERM, significantly decreased the frequency and intensity of epistaxis, while also improving hemoglobin levels as early as one month after treatment with 20 mg/day [26]. In this case, the increase of ENG and ALK1 was not only observed in experiments in vitro with ECs treated with bazedoxifene, but also, in vivo, by measuring ENG and ALK1 levels in macrophages derived from patients before and after bazedoxifene treatment. Bazedoxifene was also designed as orphan drug for HHT in 2014 by the EMA (EU/3/14/1367).
Of note, estrogens and SERMs, as hormonal receptor ligands, increase the transcription of different promoters, among them, those of coagulation factor genes. Thus, ENG and ACVRL1 are among the stimulated genes, but are not the only targets. In relation to this fact, especially when the treatment with SERMs may upregulate coagulation factors’ genes, blood tests should be performed periodically for HHT patients under SERM treatment in order to screen for prothrombotic markers and prevent thrombotic events [57].
Finally, phytoestrogens, compounds of plant origin with structural similarities with the natural estrogen 17β-estradiol, deserve some words in this section as natural plant estrogen related products. Among them, the isoflavone genistein and the coumestan resveratrol are the most relevant in studies related to HHT. Genistein is found in numerous plant species such as soy and red clover and resveratrol in grape skin and in dried fruits and nuts. These phytoestrogens show high affinity for estrogenic receptors. Genistein and resveratrol are involved in reducing inflammation, stimulating apoptosis and inhibiting angiogenesis [58,59], and might present therapeutic benefits in HHT patients as natural analogues to SERMs and estrogens.

3.2.2. Immunosuppressor Tacrolimus (FK506)

Albiñana et al. reported the efficacy of tacrolimus (FK506) in increasing endoglin and ALK1 expression [60,61]. The reason to test this drug came from a case report of an HHT patient who was administered the immunosuppressor FK506 in low doses, in combination with Aspirin and sirolimus to avoid rejection of a liver transplant. One month after the start of this treatment, it was observed that his telangiectases (both internal and external), epistaxis and anemia had all been cured [62]. Based on this report, cultured ECs were treated with tacrolimus and an increase on the protein and mRNA expression of endoglin and ALK1 and enhancement of the TGF-β1/ALK1 signaling pathway and EC functions like tubulogenesis and cell migration were observed [60,61]. These results would explain the improvement in the above-mentioned patient, by means of a partial compensation of endoglin and ALK1 haploinsufficiency. Supporting this view, five years later, Ruiz et al. reported increased ALK1 signaling pathway in HHT patient-derived EC. In an HHT animal model, tacrolimus also inhibited VEGF signaling, decreasing hypervascularization [63].
In a more clinical context, Sommer et al. published in 2019 that low doses of FK506/Advagraf decreased bleeding in an HHT patient presenting also pulmonary arterial hypertension [64]. This case report points to low doses of tacrolimus (0.5–1.5 mg/day) as the optimal range for patients with nose or GI refractory bleeding, rather than high doses (5–10 mg/day) normally used for immunosuppression in transplants [64]. An additional report by Hosman et al., including two patients dependent on HHT transfusions due to severe bleeding, demonstrates improvement after treatment with low-dose tacrolimus [65]. Currently, and according to the HHT European Federation, around 24 HHT patients are being treated “off label” with low tacrolimus doses, prescribed by HHT reference doctors, to control epistaxis and GI bleeding.
Finally, the results regarding efficacy and safety of 0.1% tacrolimus topically applied as nasal ointment of the clinical trial named TACRO have just been published. Tacrolimus nasal ointment did not result in improvement 6 weeks after finishing treatment, but the good tolerance and the significant improvement in epistaxis duration during treatment invited the researchers for a phase 3 trial on a larger patient population and a longer treatment time, with a main outcome of epistaxis duration during treatment [42].

3.2.3. N-Acetylcysteine

Based on the premise that free O2-radicals might cause precapillary sphincter abnormalities, resulting in epistaxis, Gussem et al. in 2009 wondered whether antioxidants like N-acetylcysteine (NAC) could neutralize those free O2-radicals and reduce or avoid nose bleedings. Thus, 43 HHT patients were followed-up for frequency, severity, and duration of epistaxis after a daily treatment of 600 mg NAC for 12 weeks. There was a reduction in frequency and severity of nosebleed during the day. Male patients with ENG mutations experienced a significant improvement. Only an improvement trend was found in women and patients with an ALK1 mutation [66].
Based on these results, Albiñana et al. studied the in vitro effects of NAC on endoglin and ALK1 expression levels in ECs. After NAC incubation, mRNA and protein levels of endoglin increased up to 1.5–2 folds, although there were no changes on ALK1 levels [67]. These data could suggest that the improvement experienced with their symptoms in HHT1 patients might be due, in part, due to the increase of endoglin levels after NAC treatment, which could be normalizing the nasal mucosa [66].

3.3. Strategy 3. Antiangiogenesis

Antiangiogenic strategies on HHT act on the mucosa to decrease or normalize its abnormal excessive vasculature. Two key angiogenic pathways in ECs are those triggered by VEGF and FGF.

3.3.1. Anti-VEGF and Tyrosine Kinase Inhibitors (TKI)

VEGFs specifically act on vascular EC and are a key stone in the angiogenic and lymphangiogenic process in both physiological and pathological conditions such as tumors or wound healing [68]. VEGFs play an important role in HHT since high protein levels have been reported in HHT patients [69,70,71,72].
Avastin ranks the first antiangiogenic therapeutic agent approved for advanced colorectal cancer [73]. Since then, BZ has been widely administered in other pathologies such as non-small cell lung cancer diabetic retinopathy or age-related macular degeneration [74].
The antiangiogenic properties of Avastin were successfully tested in isolated cases of HHT patients. BZ reverted the need for transplantation in a patient with HHT1 [75]. It also decreased the transfusion requirements and cardiac output in a patient with GI [76]. Thus, the French HHT Network designed a single center phase II clinical trial to address the delay in liver transplantation on HHT patients with serious liver complication [27]. BZ significantly decreased the cardiac output and reduced episodes of epistaxis. Nevertheless, symptoms did not disappear after withdrawal of the drug, making Avastin unsuitable as a surrogated alternative for orthotopic liver transplant (OLT) in HHT. These results supported the designation of BZ as orphan drug for HHT in 2014 (EU/3/14/1390).
It is very difficult to determine the optimum time to perform OLT in severe complicated liver venous malformations (VMs) in HHT. OLT is a radical cure for liver VMs and it should be the therapeutic choice in patients under the age of 65 years due to its excellent outcomes, being BZ probably a better option for patients over 65, much more susceptible to higher risk derived from surgery [77].
BZ has been also administered for very severe epistaxis. Despite of its good results decreasing epistaxis and GI after intravenous administration, it has also serious side effects. Therefore, in those patients where no other option is available, an individualized BZ treatment should be supplied; since HHT is a chronic disease [27,77,78]. This individualized re-dosing strategy will not compromise the patient’s safety or quality of life and will significantly reduce the costs [79].
BZ has also been assayed topically as nasal spray for epistaxis. The NOSE assay (under the Cure HHT support in USA, 2011–2015) and the French Ellipse clinical trial (2011–2012) ran in parallel. Unfortunately, no significant improvement could be demonstrated for the BZ vs. saline solution spray [28,29].
An alternative therapeutic approach for reducing epistaxis and GI bleeding caused by the over activated VEGF pathway is the blockade of the tyrosine-kinase activity of the VEGF receptor. As a proof of concept, the therapeutic effect of the TKI GW771806 (a pazopanib analogue), was tested in an Alk1-inducible knockout (iKO) murine HHT2 model. The oral administration of GW771806 significantly improved anemia and GI bleeding in HHT2 mice [80]. Unfortunately, its corresponding phase II human trial designed to follow-up adult HHT patients with significant epistaxis, anemia, or with transfusions could not be completed. A prospective, multi-center, open-label, dose-escalating study on pazopanib has also been published and the results show promising improvements in hemoglobin levels and epistaxis in treated patients [81].
Related to pazopanib and in a further step, nintedanib, a TKI targeting growth factor receptors involved in angiogenesis: platelet-derived growth factor receptor (PDGFR), FGFR and VEGFR, will be assayed as a therapeutic drug in a clinical trial. Nintedanib treatment in combination with rapamycin, synergizes to completely block the AVMs in HHT mice pre-clinical models [82]. This has been the main rationale to continue with nintedanib in clinical trials. In that sense, Epicure, a randomized, multicenter, phase II, double-blind placebo-controlled study promoted by the French Hospices Civils de Lyon, has started its recruitment in 2019. Epicure will test the antiangiogenic benefits of the TKI nintedanib in epistaxis. Initially, patients will be monitored for 24 weeks: 12-weeks of oral treatment plus 12-weeks of follow-up. Theoretically, nintedanib, as a non-specific/wide range TKI, should allow a reduction of epistaxis in HHT [83].
Lastly, in this section dealing with drugs interfering with the VEGF signaling pathway, thalidomide deserves special mention, since it has been used for epistaxis and GI bleeding in HHT. Its mechanism of action was published in 2010 [35] and since then, several case reports and clinical trials have been performed (Table 2 and Table 3) prior to its designation as an orphan drug (Table 4). Evidence supporting thalidomide compares favorably in cases of serious and refractory GI and nosebleeds. However, risk vs. benefit should be carefully studied, because of the reported side effects for thalidomide [78]. A derivative of thalidomide with potentially fewer side effects, pomalidomide, has been promoted for a multicenter randomized double-blind placebo controlled clinical trial currently ongoing sponsored by the NIH (Table 2).

3.3.2. Non-Selective Adrenergic β-blockers

Non-selective adrenergic β-blockers of receptors β1 and β2 such as the known propranolol and timolol, have shown antiangiogenic properties related to vasoconstriction, inhibition of EC migration and proliferation and reduced VEGF expression [30,84,85,86]. Given that an excessive activation of the VEGF pathway is involved in the development of abnormal telangiectases, the properties of these non-selective adrenergic β-blockers may be useful topically. Propranolol and timolol have been used as effective therapies to treat superficial infantile hemangiomas [84,85,86] and could be considered as a potential treatment option for HHT patients.
The use of topical timolol has been described in some case reports as well as in clinical trials/studies of HHT. According to several reports, topical timolol (0.5% ophthalmic solution) clearly improved the frequency and severity of epistaxis [87,88]. Those studies were done in individual patients as well as in larger groups of HHT patients, with clear positive results in all cases. Even though no secondary adverse effects were observed in these cases, there are some contraindications for its applications which should be kept in mind when prescribing, because β-blockers can cause respiratory and cardiovascular problems. In fact, β-blockers are metabolized in the liver by CYP2D6 and a decreased expression of this enzyme, either by concomitant treatment with CYP2D6 inhibitors or by genetic variants, may lead to strong sinus bradycardia [89,90]. Timolol has also been proved to be an efficient treatment at lower doses (0.1% ophthalmic solution-timogel) in decreasing the extension and appearance of mucocutaneous telangiectases in an HHT clinical study, showing 100% and 75% improvement in HHT2 and HHT1 patients, respectively [91].
Propranolol has also been administred topically in gel formulation and systemically in tablets with very promising results, although the last method could be associated with the above-mentioned side effects, which must be considered before prescribing.
There are several studies supporting the improvement in HHT patients after propranolol topical administration. In a pilot study done with six patients, in which 1.5% propranolol gel was applied on the nasal mucosa (0.5 mL/day per nostril) the severity of epistaxis and the number of blood transfusions pre and post-administration were reduced fast and significantly [92]. As continuation of this study, the same group recently finished a double-blind placebo-controlled study to assess the efficacy and safety of topical propranolol for moderate–severe epistaxis in 24 patients with HHT [93]. The combination of sclerotherapy with polydocanol 1% and the use of propranolol cream at 0.5% prepared in a hospital pharmacy was evaluated in a cross-sectional study of 38 HHT patients. This combined therapy significantly reduced the frequency and severity of epistaxis, with an Epistaxis Severity Score (ESS) improvement of 5 points (from 6.9  ±  2.6 at the beginning to 1.9  ±  1.3 after the therapy, p <  0.05); and increased the quality of life of these patients (in a 5D scale, from 0.66  ±  0.27 before therapy to 0.93  ±  0.12 after the therapy p <  0.05) [94].
On the other hand, systemic uptake of propranolol has some side effects such as bradycardia and hypotension. Therefore, propranolol could be used in a systemic way only in HHT patients who do not have a low blood pressure. A clinical study with oral propranolol (40–120 mg/day) was done in seven hypertensive HHT patients. Among them, HHT epistaxis disappeared completely in five out of seven, while in the other two the bleeding reduction was highly significant [95].

3.3.3. Antiangiogenesis by FGF Ligand Blocking

The FGF family is considered one of the largest families of polypeptide growth factors. FGFs interact with membrane tyrosine kinase receptors (FGF Receptors, FGFRs) through which they signal and exert their diverse biological functions. FGF-1 and FGF-2 were the first two pure polypeptides discovered among all FGFs and are considered one of the most potent factors promoting angiogenesis [96,97]. Later on, more factors promoting angiogenesis were described. FGFs constitutively cooperate with VEGF promoting the proliferation of EC [98] and inducing angiogenesis [99]. Consequently, FGF inhibition constitutes an alternative to the antiangiogenic effect of VEGF, becoming an interesting new therapeutic approach to treat diseases caused by uncontrolled angiogenesis. Many of the characteristics summarized previously suggest that the inhibition of the FGF signaling pathways could be an appropriate treatment to inhibit the abnormal vascularization of HHT patients [100].
FGF signaling may be inhibited in vitro and in vivo with chemical compounds. One of these products is the anion dihydroxy benzene sulfonate (2,5, DHBS), also known as dobesilate. Dobesilate is commercially available as tablets of its calcium and N-ethylene ethanamine salts (Doxium and Dicynone, respectively), or as injectable solution (Dicynone or etamsylate). Experiments done in vitro with primary cultures from healthy and HHT derived EC, show that etamsylate acts as an antiangiogenic factor, inhibiting wound healing and EC tubulogenesis [31]. A pilot clinical trial (EudraCT: 2016–003982–24, see Table 3) was performed with 12 HHT patients treated with a topical spray of etamsylate twice a day for 4 weeks. The HHT-ESS and other pertinent parameters were analyzed and registered. The significant reduction in the HHT-ESS scale (pre-treatment 4.1 vs. post-treatment 2.8), together with the lack of significant side effects, allowed the designation of topical etamsylate as a new orphan drug for epistaxis in HHT patients in 2018 (EU/3/10/18/2087) [31].

4. Conclusions

The currently available pharmacological treatments for HHT are summarized according to their mechanism of action on Figure 3. The drugs here included may be used on an individual level; treatment for rare diseases should follow the premises of personalized medicine, relying on the reference doctor expertise. A first-line treatment to avoid or decrease epistaxis or GI bleeding is to reinforce the speed and stability of coagulation with antifibrinolytics, preferentially TA. The only contraindication may apply to patients with risk of thrombosis. Doses vary from 1.5 g/day up to 3 g/day in episodes of severe bleeding. In countries where TA is not commercially available, AC could be used instead.
For bleedings interfering with normal life, currently the best treatment option for women in fertile age are feminine hormones used for contraception. Women in peri- or post-menopausal age can benefit from the use of SERMs. Although SERMs are primarily used to prevent or treat osteoporosis, they have shown to be effective in HHT compensating partially, the haploinsufficiency present in HHT patients by increasing the protein levels of endoglin and ALK1. Raloxifene hydrochloride was designated as orphan drug by the EMA and by the FDA. Bazedoxifene acetate was also designated as orphan drug by the EMA but it is not commercialized in United States.
Among the list of drugs that increase the expression levels of endoglin and ACVRL1/ALK1, tacrolimus was demonstrated to activate the signaling of endoglin/ALK1 in ECs. It would be the treatment of choice for immunosuppression in transplanted patients. However, recent case reports have opened the possibility of using systemic tacrolimus at low, non-immunosuppressive doses, to treat HHT bleeding. Currently, around 25 patients are using tacrolimus as an “off-label” treatment and it will be very interesting to hear about the outcome of these patients. Other treatment includes NAC which increases the endoglin RNA and protein levels and can be used as an anti-inflammatory and antioxidant drug without any side effects.
BZ is used (off-label) for antiangiogenic strategy in HHT patients with severe bleeding or symptomatic liver AVMs, in order to reduce bleedings and excessive number of abnormal mucosa vessels. TKIs (pazopanib, nintenadib, sunitinib or buparlisib) and thalidomide have also been used or are planned to be used in clinical trials [22,83,101,102] (Table 3).
Another group of antiangiogenic drugs comprises the non-selective adrenergic β-blockers like propranolol and timolol. These drugs are preferentially used topically, as creams or gels. They reduce nose bleedings by decreasing and delaying the formation of telangiectases on the mucosa. Propranolol can also be used systemically, but special attention is indicated with regards to blood pressure and heart rate.
Lastly, as emerging treatments, the orphan drug designation of etamsylate for topical treatment of epistaxis opens a new perspective following the antiangiogenic strategy.
This review has delved into the various treatment strategies of HHT and the clinical trials that support these treatments. The repurposing strategy has led to the formal approval of several orphan drugs for HHT (Table 4).

Author Contributions

L.M.B. designed the project. L.M.B. wrote the manuscript with the contribution of V.A., A.M.C., E.G.-V., I.d.R.-P., and L.R.-P., V.A. and A.M.C. designed the figures. V.A., A.M.C., E.G.-V., I.d.R.-P., L.R.-P., proofread the text. C.B. revised the manuscript and provided funding. L.M.B. supervised the project and provided funding. All authors discussed the results and contributed to the final manuscript. All authors have read and agreed to the published version of the manuscript.


This research was funded by Ministry of Economy and Competitivity, grant number SAF2017-83351-R to L.M.B.


In memoriam of José Sánchez Andújar, who passed away on 22 May 2020. He was a founder member and the first President of the Spanish Association of HHT patients.

Conflicts of Interest

The authors declare no conflict of interest.


ACAminocaproic acid
ACVRL1/ALK1Activin Receptor-Like Kinase 1
AVMArteriovenous Malformation
BMP9Bone Morphogenetic Protein 9
CMCapillary Malformation
CYP2D6Cytochrome P450 2D6
ECsEndothelial Cells
EMAEuropean Medicine Agency
EPHB4Ephrin Type-B Receptor 4
EREstrogen Receptor
ESSEpistaxis Severity Score
FDAFood and Drug Administration
FGFFibroblast Growth Factor
HHTHereditary Hemorrhagic Telangiectasia
iKOinducible Knockout
JPHTJuvenile Polyposis/HHT
MADH4/Smad4Mothers Against Decapentaplegic Homolog 4
mRNAmessenger Ribonucleic Acid
OLTOrthotopic Liver Transplant
PDGFPlatelet Derived Growth Factor
RANKReceptor Activator of Nuclear Factor κ B
RANK-LReceptor Activator of Nuclear Factor κ B Ligand
RASA1RAS P21 Protein Activator 1
SERMsSelective Estrogen Receptor Modulator
TATranexamic Acid
TFRETranscription Factor Regulatory Element
TGF-βTransforming Growth Factor β
VEGFVascular Endothelial Growth Factor
VMVenous Malformation


  1. Shovlin, C.L.; Guttmacher, A.E.; Buscarini, E.; Faughnan, M.E.; Hyland, R.H.; Westermann, C.J.J.; Kjeldsen, A.D.; Plauchu, H. Diagnostic criteria for Hereditary Hemorrhagic Telangiectasia (Rendu- Osler-Weber Syndrome). Am. J. Med. Genet. 2000, 91, 66–67. [Google Scholar] [CrossRef]
  2. Shovlin, C.L. Hereditary haemorrhagic telangiectasia: Pathophysiology, diagnosis and treatment. Blood Rev. 2010, 24, 203–219. [Google Scholar] [CrossRef]
  3. Shovlin, C.L. Pulmonary arteriovenous malformations. Am. J. Respir. Crit. Care Med. 2014, 190, 1217–1228. [Google Scholar] [CrossRef] [PubMed]
  4. Kjeldsen, A.D.; Vase, P.; Green, A. Hereditary haemorrhagic telangiectasia: A population-based study of prevalence and mortality in Danish patients. J. Intern. Med. 1999, 245, 31–39. [Google Scholar] [CrossRef] [PubMed]
  5. Jessurun, G.A.J.; Kamphuis, D.J.; Van der Zande, F.H.R.; Nossent, J.C. Cerebral arteriovenous malformations in the Netherlands Antilles. High prevalence of hereditary hemorrhagic telangiectasia-related single and multiple cerebral arteriovenous malformations. Clin. Neurol. Neurosurg. 1993, 95, 193–198. [Google Scholar] [CrossRef]
  6. McAllister, K.A.; Grogg, K.M.; Johnson, D.W.; Gallione, C.J.; Baldwin, M.A.; Jackson, C.E.; Helmbold, E.A.; Markel, D.S.; McKinnon, W.C.; Murrel, J.; et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat. Genet. 1994, 8, 345–351. [Google Scholar] [CrossRef]
  7. Johnson, D.W.; Berg, J.N.; Baldwin, M.A.; Gallione, C.J.; Marondel, I.; Yoon, S.J.; Stenzel, T.T.; Speer, M.; Pericak-Vance, M.A.; Diamond, A.; et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type. Nat. Genet. 1996, 13, 189–195. [Google Scholar] [CrossRef]
  8. Gallione, C.J.; Repetto, G.M.; Legius, E.; Rustgi, A.K.; Schelley, S.L.; Tejpar, S.; Mitchell, G.; Drouin, É.; Westermann, C.J.J.; Marchuk, D.A. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet. 2004, 363, 852–859. [Google Scholar] [CrossRef]
  9. Duan, X.Y.; Guo, D.C.; Regalado, E.S.; Shen, H.; Coselli, J.S.; Estrera, A.L.; Safi, H.J.; Bamshad, M.J.; Nickerson, D.A.; LeMaire, S.A.; et al. SMAD4 rare variants in individuals and families with thoracic aortic aneurysms and dissections. Eur. J. Hum. Genet. 2019, 27, 1054–1060. [Google Scholar] [CrossRef]
  10. Cole, S.G.; Begbie, M.E.; Wallace, G.M.F.; Shovlin, C.L.L. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J. Med. Genet. 2005, 42, 577–582. [Google Scholar] [CrossRef]
  11. Bayrak-Toydemir, P.; McDonald, J.; Akarsu, N.; Toydemir, R.M.; Calderon, F.; Tuncali, T.; Tang, W.; Miller, F.; Mao, R. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am. J. Med. Genet. A 2006, 140, 2155–2162. [Google Scholar] [CrossRef] [PubMed]
  12. Wooderchak-Donahue, W.L.; McDonald, J.; O’Fallon, B.; Upton, P.D.; Li, W.; Roman, B.L.; Young, S.; Plant, P.; Fülöp, G.T.; Langa, C.; et al. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am. J. Hum. Genet. 2013, 93, 530–537. [Google Scholar] [CrossRef] [PubMed]
  13. Bayrak-Toydemir, P.; Stevenson, D. Capillary Malformation-Arteriovenous Malformation Syndrome. In GeneReviews®; Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Eds.; University of Washington: Seattle, WA, USA, 1993. [Google Scholar] [PubMed]
  14. Morales-Angulo, C.; Del Valle-Zapico, A. Hereditary hemorrhagic telangiectasia. Otolaryngol. Head Neck Surg. 1998, 119, 293. [Google Scholar] [PubMed]
  15. AAssar, O.S.; Friedman, C.M.; White, R.I. The Natural History of Epistaxis in Hereditary Hemorrhagic Telangiectasia. Laryngoscope 1991, 101, 977–980. [Google Scholar] [CrossRef] [PubMed]
  16. Geisthoff, U.W.; Schneider, G.; Fischinger, J.; Plinkert, P.K. Hereditäre hämorrhagische teleangiektasie (Morbus Osler). Eine interdisziplinäre herausforderung. HNO 2002, 50, 114–128. [Google Scholar] [CrossRef] [PubMed]
  17. Guttmacher, A.E.; Marchuk, D.A.; White, R.I. Hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 1995, 333, 918–924. [Google Scholar] [CrossRef]
  18. Ingrosso, M.; Sabbà, C.; Pisani, A.; Principi, M.; Gallitelli, M.; Cirulli, A.; Francavilla, A. Evidence of small-bowel involvement in hereditary hemorrhagic telangiectasia: A capsule-endoscopic study. Endoscopy 2004, 36, 1074–1079. [Google Scholar] [CrossRef]
  19. Vase, P.; Grove, O. Gastrointestinal Lesions in Hereditary Hemorrhagic Telangiectasia. Gastroenterology 1986, 91, 1079–1083. [Google Scholar] [CrossRef]
  20. Snellings, D.A.; Gallione, C.J.; Clark, D.S.; Vozoris, N.T.; Faughnan, M.E.; Marchuk, D.A. Somatic Mutations in Vascular Malformations of Hereditary Hemorrhagic Telangiectasia Result in Bi-allelic Loss of ENG or ACVRL1. Am. J. Hum. Genet. 2019, 105, 894–906. [Google Scholar] [CrossRef]
  21. Kasthuri, R.S.; Montifar, M.; Nelson, J.; Kim, H.; Lawton, M.T.; Faughnan, M.E. Prevalence and predictors of anemia in hereditary hemorrhagic telangiectasia. Am. J. Hematol. 2017, 92, E591–E593. [Google Scholar] [CrossRef]
  22. Robert, F.; Desroches-Castan, A.; Bailly, S.; Dupuis-Girod, S.; Feige, J.J. Future treatments for hereditary hemorrhagic telangiectasia. Orphanet J. Rare. Dis. 2020, 15, 4. [Google Scholar] [CrossRef] [PubMed]
  23. Pérez Del Molino, A.; Zarrabeitia, R.; Fernández-L, A.; Botella, L.M. Efficacy of tranexamic acid in a patient with hereditary haemorrhagic telangiectasia and massive epistaxis. Med. Clin. (Barc.) 2004, 123, 118–119. [Google Scholar] [CrossRef]
  24. Fernandez-L, A.; Garrido-Martin, E.M.; Sanz-Rodriguez, F.; Ramirez, J.R.; Moralez-Angulo, C.; Zarrabeltia, R.; Perez-Molino, A.; Bernabéu, C.; Botella, L.M. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): Regulation of ALK-I/endoglin pathway in endothelial cells. Thromb. Haemost. 2007, 97, 254–262. [Google Scholar] [CrossRef] [PubMed]
  25. Albiñana, V.; Bernabeu-Herrero, M.E.; Zarrabeitia, R.; Bernabeu, C.; Botella, L.M. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells. Thromb. Haemost. 2010, 103, 525–534. [Google Scholar] [CrossRef] [PubMed]
  26. Zarrabeitia, R.; Ojeda-Fernandez, L.; Recio, L.; Bernabéu, C.; Parra, J.A.; Albiñana, V.; Botella, L.M. Bazedoxifene, a new orphan drug for the treatment of bleeding in hereditary haemorrhagic telangiectasia. Thromb. Haemost. 2016, 115, 1167–1177. [Google Scholar] [CrossRef]
  27. Dupuis-Girod, S.; Ginon, I.; Saurin, J.C.; Marion, D.; Guillot, E.; Decullier, E.; Roux, A.; Carette, M.F.; Gilbert-Dussardier, B.; Hatron, P.Y.; et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA J. Am. Med. Assoc. 2012, 307, 948–955. [Google Scholar] [CrossRef]
  28. Whitehead, K.J.; Sautter, N.B.; McWilliams, J.P.; Chakinala, M.M.; Merlo, C.A.; Johnson, M.H.; James, M.; Everett, E.M.; Clancy, M.S.; Faughnan, M.E.; et al. Effect of topical intranasal therapy on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia: A randomized clinical trial. JAMA J. Am. Med. Assoc. 2016, 316, 943–951. [Google Scholar] [CrossRef]
  29. Dupuis-Girod, S.; Ambrun, A.; Decullier, E.; Fargeton, A.E.; Roux, A.; Bréant, V.; Colombet, B.; Rivière, S.; Cartier, C.; Lacombe, P.; et al. Effect of bevacizumab nasal spray on epistaxis duration in hereditary hemorrhagic telangectasia: A randomized clinical trial. JAMA J. Am. Med. Assoc. 2016, 316, 934–942. [Google Scholar] [CrossRef]
  30. Albiñana, V.; Recio-Poveda, L.; Zarrabeitia, R.; Bernabéu, C.; Botella, L.M. Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia. Thromb. Haemost. 2012, 108, 41–53. [Google Scholar] [CrossRef]
  31. Albiñana, V.; Giménez-Gallego, G.; García-Mato, A.; Palacios, P.; Recio-Poveda, L.; Cuesta, A.-M.; Patier, J.-L.; Botella, L.-M. Topically Applied Etamsylate: A New Orphan Drug for HHT-Derived Epistaxis (Antiangiogenesis through FGF Pathway Inhibition). TH Open 2019, 3, e230–e243. [Google Scholar] [CrossRef]
  32. Geisthoff, U.W.; Seyfert, U.T.; Kübler, M.; Bieg, B.; Plinkert, P.K.; König, J. Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid—A double blind placebo-controlled cross-over phase IIIB study. Thromb. Res. 2014, 134, 565–571. [Google Scholar] [CrossRef] [PubMed]
  33. Yaniv, E.; Preis, M.; Hadar, T.; Shvero, J.; Haddad, M. Antiestrogen therapy for Hereditary hemorrhagic telangiectasia: A double-blind placebo-controlled clinical trial. Laryngoscope 2009, 119, 284–288. [Google Scholar] [CrossRef] [PubMed]
  34. Gaillard, S.; Dupuis-Girod, S.; Boutitie, F.; Rivière, S.; Morinière, S.; Hatron, P.Y.; Manfredi, G.; Kaminsky, P.; Capitaine, A.L.; Roy, P.; et al. Tranexamic acid for epistaxis in hereditary hemorrhagic telangiectasia patients: A European cross-over controlled trial in a rare disease. J. Thromb. Haemost. 2014, 12, 1494–1502. [Google Scholar] [CrossRef] [PubMed]
  35. Lebrin, F.; Srun, S.; Raymond, K.; Martin, S.; Van Den Brink, S.; Freitas, C.; Bréant, C.; Mathivet, T.; Larrivée, B.; Thomas, J.L.; et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat. Med. 2010, 16, 420–428. [Google Scholar] [CrossRef]
  36. Riss, D.; Burian, M.; Wolf, A.; Kranebitter, V.; Kaider, A.; Arnoldner, C. Intranasal submucosal bevacizumab for epistaxis in hereditary hemorrhagic telangiectasia: A double-blind, randomized, placebo-controlled trial. Head Neck. 2015, 37, 783–787. [Google Scholar] [CrossRef]
  37. Dupuis-Girod, S.; Ambrun, A.; Decullier, E.; Samson, G.; Roux, A.; Fargeton, A.E.; Rioufol, C.; Schwiertz, V.; Disant, F.; Chapuis, F.; et al. ELLIPSE Study: A Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia. MAbs 2014, 6, 794–799. [Google Scholar] [CrossRef]
  38. Shovlin, C.L.; Gilson, C.; Busbridge, M.; Patel, D.; Shi, C.; Dina, R.; Abdulla, F.N.; Awan, I. Can Iron Treatments Aggravate Epistaxis in Some Patients With Hereditary Hemorrhagic Telangiectasia? Laryngoscope 2016, 126, 2468–2474. [Google Scholar] [CrossRef]
  39. Lee, J.M.; Wu, V.; Faughnan, M.E.; Lasso, A.; Figol, A.; Kilty, S.J. Prospective pilot study of Floseal® for the treatment of anterior epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT). J. Otolaryngol. Head Neck Surg. 2019, 48, 48. [Google Scholar] [CrossRef]
  40. Dupuis-Girod, S.; Pitiot, V.; Bergerot, C.; Fargeton, A.E.; Beaudoin, M.; Decullier, E.; Bréant, V.; Colombet, B.; Philouze, P.; Faure, F.; et al. Efficacy of TIMOLOL nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia. A double-blind, randomized, placebo-controlled trial. Sci. Rep. 2019, 9, 1986. [Google Scholar] [CrossRef]
  41. Kroon, S.; Snijder, R.J.; Mager, J.J.; Post, M.C.; Tenthof van Noorden, J.; Van Geenen, E.J.M.; Drenth, J.P.H.; Grooteman, K.V. Octreotide for gastrointestinal bleeding in hereditary hemorrhagic telangiectasia: A prospective case series. Am. J. Hematol. 2019, 94, E247–E249. [Google Scholar] [CrossRef]
  42. Dupuis-Girod, S.; Fargeton, A.-E.; Grobost, V.; Rivière, S.; Beaudoin, M.; Decullier, E.; Bernard, L.; Bréant, V.; Colombet, B.; Philouze, P.; et al. Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial. J. Clin. Med. 2020, 9, 1262. [Google Scholar] [CrossRef] [PubMed]
  43. Masoudi-Sobhanzadeh, Y.; Omidi, Y.; Amanlou, M.; Masoudi-Nejad, A. Drug databases and their contributions to drug repurposing. Genomics 2020, 112, 1087–1095. [Google Scholar] [CrossRef] [PubMed]
  44. Kwaan, H.C.; Silverman, S. Fibrinolytic Activity in Lesions of Hereditary Hemorrhagic Telangiectasia. Arch. Dermatol. 1973, 107, 571–573. [Google Scholar] [CrossRef] [PubMed]
  45. Watanabe, M.; Hanawa, S.; Morishima, T. Fibrinolytic activity in cutaneous lesions of hereditary hemorrhagic telangiectasia. Nippon Hifuka Gakkai Zasshi. Jpn. J. Dermatol. 1985, 95, 11–16. [Google Scholar]
  46. Saba, H.I.; Morelli, G.A.; Logrono, L.A. Treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N. Engl. J. Med. 1994, 330, 1789–1790. [Google Scholar] [CrossRef]
  47. Annichino-Bizzacchi, J.M.; Facchini, R.M.; Torresan, M.Z.; Arruda, V.R. Hereditary hemorrhagic telangiectasia response to aminocaproic acid treatment. Thromb. Res. 1999, 96, 73–76. [Google Scholar] [CrossRef]
  48. Korzenik, J.R.; Topazian, M.D.; White, R.; Saba, H.I.; Morelli, G.; Logrono, L. Treatment of bleeding in hereditary hemorrhagic telangiectasia with aminocaproic acid. N. Engl. J. Med. 1994, 331, 1236. [Google Scholar]
  49. Mannucci, P.M. Hemostatic drugs. N. Engl. J. Med. 1998, 339, 245–253. [Google Scholar] [CrossRef]
  50. Shovlin, C.L.; Sulaiman, N.L.; Govani, F.S.; Jackson, J.K.; Begbie, M.E. Elevated factor VIII in hereditary haemorrhagic telangiectasia (HHT): Association with venous thromboembolism. Thromb. Haemost. 2007, 98, 1031–1039. [Google Scholar]
  51. Sabba, C.; Gallitelli, M.; Palasciano, G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N. Engl. J. Med. 2001, 345, 926. [Google Scholar] [CrossRef]
  52. Kearns, A.E.; Khosla, S.; Kostenuik, P.J. Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr. Rev. 2008, 29, 155–192. [Google Scholar] [CrossRef] [PubMed]
  53. Longacre, A.V.; Gross, C.P.; Gallitelli, M.; Henderson, K.J.; White, R.I.; Proctor, D.D. Diagnosis and management of gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am. J. Gastroenterol. 2003, 98, 59–65. [Google Scholar] [CrossRef] [PubMed]
  54. Yaniv, E.; Preis, M.; Shvero, J.; Nageris, B.; Hadar, T. Anti-estrogen therapy for hereditary hemorrhagic telangiectasia—A long-term clinical trial. Rhinology 2011, 49, 214–216. [Google Scholar] [CrossRef] [PubMed]
  55. Haq, A.U.; Glass, J.; Netchvolodoff, C.V.; Bowen, L.M. Hereditary hemorrhagic telangiectasia and danazol. Ann. Intern. Med. 1988, 109, 171. [Google Scholar] [CrossRef]
  56. Zacharski, L.R.; Dunbar, S.D.; Newsom, W.A. Hemostatic effects of tamoxifen in hereditary hemorrhagic telangiectasia. Thromb. Haemost. 2001, 85, 371–372. [Google Scholar] [PubMed]
  57. Nelson, E.R.; Wardell, S.E.; McDonnell, D.P. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis. Bone 2013, 53, 42–50. [Google Scholar] [CrossRef]
  58. Athar, M.; Back, J.H.; Kopelovich, L.; Bickers, D.R.; Kim, A.L. Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 2009, 486, 95–102. [Google Scholar] [CrossRef]
  59. Park, E.; Lee, S.M.; Jung, I.K.; Lim, Y.; Kim, J.H. Effects of genistein on early-stage cutaneous wound healing. Biochem. Biophys. Res. Commun. 2011, 410, 514–519. [Google Scholar] [CrossRef]
  60. Albiñana, V.; Sanz-Rodríguez, F.; Recio-Poveda, L.; Bernabéu, C.; Botella, L.M. Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-β1 signaling in endothelial cells. Mol. Pharmacol. 2011, 79, 833–843. [Google Scholar] [CrossRef]
  61. Albiñana, V.; Velasco, L.; Zarrabeitia, R.; Botella, L.M. Tacrolimus as a therapeutic drug in hereditary hemorrhagic telangiectasia (HHT). In Tacrolimus: Effectiveness, Safety and Drug Interactions; Nova Science Publishers: Hauppauge, NY, USA, 2013; pp. 163–172. ISBN 9781628083668. [Google Scholar]
  62. Skaro, A.I.; Marotta, P.J. Regression of cutaneous and gastrointestinal telangiectasia with sirolimus and aspirin in a patient with hereditary hemorrhagic telangiectasia. Ann. Intern. Med. 2006, 144, 226–227. [Google Scholar]
  63. Ruiz, S.; Chandakkar, P.; Zhao, H.; Papoin, J.; Chatterjee, P.K.; Christen, E.; Metz, C.N.; Blanc, L.; Campagne, F.; Marambaud, P. Tacrolimus rescues the signaling and gene expression signature of endothelial ALK1 loss-of-function and improves HHT vascular pathology. Hum. Mol. Genet. 2017, 26, 4786–4798. [Google Scholar] [CrossRef] [PubMed]
  64. Sommer, N.; Droege, F.; Gamen, K.E.; Geisthoff, U.; Gall, H.; Tello, K.; Richter, M.J.; Deubner, L.M.; Schmiedel, R.; Hecker, M.; et al. Treatment with low-dose tacrolimus inhibits bleeding complications in a patient with hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. Pulm. Circ. 2019, 9, 2045894018805406. [Google Scholar] [CrossRef] [PubMed]
  65. Hosman, A.; Kroon, S.; Vorselaars, V.; Doef, H.; Post, M.; Snijder, R.; Mager, J. Tacrolimus treatment for two rare complications caused by hereditary haemorrhagic telangiectasia: A description of two cases. Angiogenesis 2019, 22, 629. [Google Scholar]
  66. De Gussem, E.M.; Snijder, R.J.; Disch, F.J.; Zanen, P.; Westermann, C.J.J.; Mager, J.J. The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: A pilot study. Rhinology 2009, 47, 85–88. [Google Scholar] [PubMed]
  67. Albiñana, V. Ensayos Preclínicos In Vitro con Células Endoteliales, Como Aproximaciones Terapéuticas Farmacológicas Para la Telangiectasia Hemorrágica Hereditaria (HHT). Ph.D. Thesis, Universidad Complutense, Madrid, Spain, 28 June 2012. [Google Scholar]
  68. Roy, H.; Bhardwaj, S.; Ylä-Herttuala, S. Biology of vascular endothelial growth factors. FEBS Lett. 2006, 580, 2879–2887. [Google Scholar] [CrossRef]
  69. Cirulli, A.; Liso, A.; D’Ovidio, F.; Mestice, A.; Pasculli, G.; Gallitelli, M.; Rizzi, R.; Specchia, G.; Sabbà, C. Vascular endothelial growth factor serum levels are elevated in patients with hereditary hemorrhagic telangiectasia. Acta Haematol. 2003, 110, 29–32. [Google Scholar] [CrossRef]
  70. Sadick, H.; Riedel, F.; Naim, R.; Goessler, U.; Hörmann, K.; Hafner, M.; Lux, A. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-β1 as well as high ALK1 tissue expression. Haematologica 2005, 90, 818–828. [Google Scholar]
  71. Peng, H.L.; Hu, G.Y.; Zhang, G.S.; Gong, F.J. Analysis of angiogenesis related proteins and its implication in type-2 hereditary hemorrhagic telangiectasia. Zhonghua Xue Ye Xue Za Zhi 2006, 27, 616–620. [Google Scholar]
  72. Botella, L.M.; Albiñana, V.; Ojeda-Fernandez, L.; Recio-Poveda, L.; Bernabéu, C. Research on potential biomarkers in hereditary hemorrhagic telangiectasia. Front. Genet. 2015, 6, 115. [Google Scholar] [CrossRef]
  73. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004, 350, 2335–2342. [Google Scholar] [CrossRef]
  74. Michels, S.; Rosenfeld, P.J.; Puliafito, C.A.; Marcus, E.N.; Venkatraman, A.S. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: Twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005, 112, 1035–1047. [Google Scholar] [CrossRef] [PubMed]
  75. Mitchell, A.; Adams, L.A.; MacQuillan, G.; Tibballs, J.; Vanden Driesen, R.; Delriviere, L. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transplant. 2008, 14, 210–213. [Google Scholar] [CrossRef] [PubMed]
  76. Flieger, D.; Hainke, S.; Fischbach, W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann. Hematol. 2006, 85, 631–632. [Google Scholar] [CrossRef] [PubMed]
  77. Dupuis-Girod, S.; Buscarini, E. Hereditary hemorrhagic telangiectasia: To transplant or not to transplant? Liver Int. 2016, 36, 1741–1744. [Google Scholar] [CrossRef] [PubMed]
  78. Buscarini, E.; Botella, L.M.; Geisthoff, U.; Kjeldsen, A.D.; Mager, H.J.; Pagella, F.; Suppressa, P.; Zarrabeitia, R.; Dupuis-Girod, S.; Shovlin, C.L.; et al. Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia. Orphanet. J. Rare Dis. 2019, 14, 28. [Google Scholar] [CrossRef]
  79. Albitar, H.A.; Choby, G.; Pruthi, R.; O’Brien, E.; Stokken, J.; Kamath, P.; Leise, M.; Gallo De Moraes, A.; Cajigas, H.; Dubrock, H.; et al. Intravenous bevacizumab in HHT-related bleeding: Significant inter-individual variability in the need for maintenance therapy. Angiogenesis 2019, 22, 589–590. [Google Scholar]
  80. Kim, Y.H.; Kim, M.J.; Choe, S.W.; Sprecher, D.; Lee, Y.J.; Oh, S.P. Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia. J. Thromb. Haemost. 2017, 15, 1095–1102. [Google Scholar] [CrossRef]
  81. Faughnan, M.E.; Gossage, J.R.; Chakinala, M.M.; Oh, S.P.; Kasthuri, R.; Hughes, C.C.W.; McWilliams, J.P.; Parambil, J.G.; Vozoris, N.; Donaldson, J.; et al. Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia. Angiogenesis 2019, 22, 145–155. [Google Scholar] [CrossRef]
  82. Ruiz, S.; Zhao, H.; Chandakkar, P.; Papoin, J.; Choi, H.; Nomura-Kitabayashi, A.; Patel, R.; Gillen, M.; Diao, L.; Chatterjee, P.K.; et al. Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models. Clin. Investig. 2020, 130, 942–957. [Google Scholar] [CrossRef]
  83. Kovacs-Sipos, E.; Holzmann, D.; Scherer, T.; Soyka, M.B. Nintedanib as a novel treatment option in hereditary haemorrhagic telangiectasia. BMJ. Case. Rep. 2017, 2017, bcr2017219393. [Google Scholar] [CrossRef]
  84. Léauté-Labrèze, C.; De La Roque, E.D.; Hubiche, T.; Boralevi, F.; Thambo, J.B.; Taïeb, A. Propranolol for severe hemangiomas of infancy. N. Engl. J. Med. 2008, 358, 2649–2651. [Google Scholar] [CrossRef] [PubMed]
  85. Storch, C.H.; Hoeger, P.H. Propranolol for infantile haemangiomas: Insights into the molecular mechanisms of action. Br. J. Dermatol. 2010, 163, 269–274. [Google Scholar] [CrossRef] [PubMed]
  86. Sánchez-Carpintero, I.; Ruiz-Rodriguez, R.; López-Gutiérrez, J.C. Propranolol in the treatment of infantile hemangioma: Clinical effectiveness, risks, and recommendations. Actas Dermosifiliogr. 2011, 102, 766–779. [Google Scholar] [CrossRef] [PubMed]
  87. Olitsky, S.E. Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Am. J. Otolaryngol. Head Neck Med. Surg. 2012, 33, 375–376. [Google Scholar] [CrossRef]
  88. Ichimura, K.; Kikuchi, H.; Imayoshi, S.; Dias, M.S. Topical application of timolol decreases the severity and frequency of epistaxis in patients who have previously undergone nasal dermoplasty for hereditary hemorrhagic telangiectasia. Auris Nasus Larynx. 2016, 43, 429–432. [Google Scholar] [CrossRef]
  89. Epperla, N.; Brilliant, M.H.; Vidaillet, H. Topical timolol for treatment of epistaxis in hereditary haemorrhagic telangiectasia associated with bradycardia: A look at CYP2D6 metabolising variants. BMJ Case. Rep. 2014, 2014, bcr2013203056. [Google Scholar] [CrossRef]
  90. Volotinen, M.; Hakkola, J.; Pelkonen, O.; Vapaatalo, H.; Mäenpää, J. Metabolism of ophthalmic timolol: New aspects of an old drug. Basic Clin. Pharmacol. Toxicol. 2011, 108, 297–303. [Google Scholar] [CrossRef]
  91. Botella, L.M.; Zarrabeitia, R.; Albinana, V.; Ojeda-Fernández, M.L.; Diez-Gonzalez, V.; Parra-Blanco, J.A. Efficacy of topical timolol for the treatment of mucocutaneous telangiectasias in patients with hereditary haemorrhagic telangiectasia. Angiogenesis 2015, 18, 594. [Google Scholar]
  92. Mei-Zahav, M.; Blau, H.; Bruckheimer, E.; Zur, E.; Goldschmidt, N. Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia—A preliminary report. J. Otolaryngol. Head Neck Surg. 2017, 46, 58. [Google Scholar] [CrossRef]
  93. Mei-Zahav, M.; Goldschmidt, N.; Bruckheimer, E.; Soudri, E. A double-blind placebo-controlled study assessing the safety and efficacy of topical propranolol for moderate–severe epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT). Angiogenesis 2019, 22, 597–598. [Google Scholar]
  94. Esteban-Casado, S.; Martín de Rosales Cabrera, A.M.; Usarralde Pérez, A.; Martínez Simón, J.J.; Zhan Zhou, E.; Marcos Salazar, M.S.; Pérez Encinas, M.; Botella Cubells, L. Sclerotherapy and Topical Nasal Propranolol: An Effective and Safe Therapy for HHT-Epistaxis. Laryngoscope 2019, 129, 2216–2223. [Google Scholar] [CrossRef] [PubMed]
  95. Patier, J.L.; Camacho Aguirre, A.; Sirgo, N.; Gonzalez Nino, I.; Suárez Carantoña, C.; Gonzalez Garcia, A.; López Rodriguez, M.; Botella, L.M. Effectiveness and safety of the treatment with oral propranolol in patients with hereditary hemorrhagic telangiectasia and bloodhypertension or atrial fibrillation: A possible anti-angiogenictreatment in epistaxis. Angiogenesis 2019, 22, 628. [Google Scholar]
  96. Thomas, K.A.; Rios-Candelore, M.; Gimenez-Gallego, G.; DiSalvo, J.; Bennett, C.; Rodkey, J.; Fitzpatrick, S. Pure brain-derived acidic fibroblast growth factor is a potent angiogenic vascular endothelial cell mitogen with sequence homology to interleukin 1. Proc. Natl. Acad. Sci. USA 1985, 82, 6409–6413. [Google Scholar] [CrossRef] [PubMed]
  97. Esch, F.; Baird, A.; Ling, N.; Ueno, N.; Hill, F.; Denoroy, L.; Klepper, R.; Gospodarowicz, D.; Böhlen, P.; Guillemin, R. Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc. Natl. Acad. Sci. USA 1985, 82, 6507–6511. [Google Scholar] [CrossRef] [PubMed]
  98. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [PubMed]
  99. Cross, M.J.; Claesson-Welsh, L. FGF and VEGF function in angiogenesis: Signalling pathways, biological responses and therapeutic inhibition. Trends. Pharmacol. Sci. 2001, 22, 201–207. [Google Scholar] [CrossRef]
  100. Loges, S.; Mazzone, M.; Hohensinner, P.; Carmeliet, P. Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited. Cancer Cell 2009, 15, 167–170. [Google Scholar] [CrossRef]
  101. Droege, F.; Thangavelu, K.; Lang, S.; Geisthoff, U. Improvement in hereditary hemorrhagic telangiectasia after treatment with the multi-kinase inhibitor Sunitinib. Ann. Hematol. 2016, 95, 2077–2078. [Google Scholar] [CrossRef]
  102. Geisthoff, U.W.; Nguyen, H.L.P.; Hess, D. Improvement in hereditary hemorrhagic telangiectasia after treatment with the phosphoinositide 3-kinase inhibitor BKM120. Ann. Hematol. 2014, 93, 703–704. [Google Scholar] [CrossRef]
Figure 1. Hereditary Hemorrhagic Telangiectasia. (A). Clinical manifestations of HHT, Curaçao criteria. Telangiectasias in ear, hands, tongue, and lips; arteriovenous malformations in internal organs, epistaxis and family history. (B). TGF-β/BMP9/10 signaling pathway in endothelial cells. Once the ligand binds to its receptor complex formed by the kinase receptors I and II, and the auxiliary receptor III (endoglin), the signaling cascade leads to the phosphorylation of Smad proteins. The translocation of the Smad protein complex into the nucleus results in transcriptional regulation on target genes. Endothelial cells (EC) express two types of type I kinase Receptors: ALK1 and ALK5.
Figure 1. Hereditary Hemorrhagic Telangiectasia. (A). Clinical manifestations of HHT, Curaçao criteria. Telangiectasias in ear, hands, tongue, and lips; arteriovenous malformations in internal organs, epistaxis and family history. (B). TGF-β/BMP9/10 signaling pathway in endothelial cells. Once the ligand binds to its receptor complex formed by the kinase receptors I and II, and the auxiliary receptor III (endoglin), the signaling cascade leads to the phosphorylation of Smad proteins. The translocation of the Smad protein complex into the nucleus results in transcriptional regulation on target genes. Endothelial cells (EC) express two types of type I kinase Receptors: ALK1 and ALK5.
Jcm 09 01766 g001
Figure 2. Scheme of Bone formation vs. Bone resorption (left). Bone remodeling is promoted by the activity of osteoclasts and osteoblasts. RANKL is a protein expressed by osteoblasts which, upon binding to its RANK receptor on the cell surface of osteoclasts and their precursors, causes RANK to stimulate and promote the adhesion of osteoclasts to bone, thus activating their function and preventing apoptosis. OPG is synthesized by the osteoblasts and acts as a decoy receptor, preventing the binding of RANKL to RANK, therefore decreasing the activity of the osteoclast and its survival [52]. For this reason, for years post-menopausal patients with diagnosed osteoporosis have been receiving estrogenic treatment, which, while correcting this imbalance in bone remodeling, also reduces the activity of the osteoclast and activates the expression of OPG. This is also capable of reducing the epistaxis of these patients [25,33,53,54]. Scheme of Estrogen Receptor (ER) signaling (right). Mechanism of action of ER on EC, in the case of the SERMs raloxifene and bazedoxifene. Upon ligand binding, the ER dimer interacts with different transcription factors (TF), promoting gene expression by binding to the TFRE (Transcription Factor Regulatory Element) in the promoter of its target genes. The expression of endoglin and ALK1 increases as a result of the interaction of the ER with Sp1, an essential factor for the expression of both genes. In women, SERMs promote a decrease in the frequency and amount of epistaxis, normalizing the nasal vasculature with concomitant improvement in osteoporosis [25,26].
Figure 2. Scheme of Bone formation vs. Bone resorption (left). Bone remodeling is promoted by the activity of osteoclasts and osteoblasts. RANKL is a protein expressed by osteoblasts which, upon binding to its RANK receptor on the cell surface of osteoclasts and their precursors, causes RANK to stimulate and promote the adhesion of osteoclasts to bone, thus activating their function and preventing apoptosis. OPG is synthesized by the osteoblasts and acts as a decoy receptor, preventing the binding of RANKL to RANK, therefore decreasing the activity of the osteoclast and its survival [52]. For this reason, for years post-menopausal patients with diagnosed osteoporosis have been receiving estrogenic treatment, which, while correcting this imbalance in bone remodeling, also reduces the activity of the osteoclast and activates the expression of OPG. This is also capable of reducing the epistaxis of these patients [25,33,53,54]. Scheme of Estrogen Receptor (ER) signaling (right). Mechanism of action of ER on EC, in the case of the SERMs raloxifene and bazedoxifene. Upon ligand binding, the ER dimer interacts with different transcription factors (TF), promoting gene expression by binding to the TFRE (Transcription Factor Regulatory Element) in the promoter of its target genes. The expression of endoglin and ALK1 increases as a result of the interaction of the ER with Sp1, an essential factor for the expression of both genes. In women, SERMs promote a decrease in the frequency and amount of epistaxis, normalizing the nasal vasculature with concomitant improvement in osteoporosis [25,26].
Jcm 09 01766 g002
Figure 3. Therapeutic strategies of pharmacological treatments in HHT. (1) Antifibrinolytic strategy; prevents the conversion of plasminogen to plasmin, thus delaying the lysis of the fibrin clot, and therefore the bleeding. (2) Upregulation strategy. The drug works by increasing the expression of the ENG or ALK1 genes, and thus resulting in increased amount of proteins, improving the BMP/TGF-β signaling and normalizing the formation of new vessels. (3) Antiangiogenesis strategy; makes disappear the excess of existing abnormal vasculature or normalizes it.
Figure 3. Therapeutic strategies of pharmacological treatments in HHT. (1) Antifibrinolytic strategy; prevents the conversion of plasminogen to plasmin, thus delaying the lysis of the fibrin clot, and therefore the bleeding. (2) Upregulation strategy. The drug works by increasing the expression of the ENG or ALK1 genes, and thus resulting in increased amount of proteins, improving the BMP/TGF-β signaling and normalizing the formation of new vessels. (3) Antiangiogenesis strategy; makes disappear the excess of existing abnormal vasculature or normalizes it.
Jcm 09 01766 g003
Table 1. Therapeutic strategies to decrease epistaxis in HHT.
Table 1. Therapeutic strategies to decrease epistaxis in HHT.
1Decrease hemorrhages stabilizing the fibrin network with antifibrinolytics
Tranexamic acid
2Stimulate ENG and ALK1 transcription to increase protein expression to partially overcome haploinsufficiency
SERMs: raloxifene, bazedoxifene
3Decrease the abnormal excessive vasculature of the nose mucosa through antiangiogenesis
By inactivating the VEGF signaling pathway
Bevacizumab, propranolol, timolol, thalidomide or pazopanib
By blocking the FGF-R signaling pathway
Table 2. Compilation of the HHT interventional clinical trials (Recruiting, Ongoing, or Unknown status).
Table 2. Compilation of the HHT interventional clinical trials (Recruiting, Ongoing, or Unknown status).
Trial Registration #CountryPhaseTitleInterventionNumber of PatientsTrial DesignOutcomeStart DateStatus
IT2Bevacizumab, an anti-angiogenic monoclonal antibody effective for prevention of hemorrhage in patients with HHT: possible regression of visceral arteriovenous malformationsBevacizumab18Single-arm, controlledFrequency of Epistaxis2008O
FR2METAFORE: Maladie de Rendu-Osler: Etude de l’Efficacité et de la tolérance du Bevacizumab utilisé pour le traitement des formes hépatiques sévères. Etude de phase IIBevacizumab25Information not availableEffect on cardiac output in patients with severe liver damage2009O
NCT02389959US4Intranasal Bevacizumab for HHT-Related EpistaxisBevacizumab40Two-arm, randomized, double-blind, placebo-controlledImprovement in ESS2014R
NCT02287558US1Pomalidomide in HHT and Transfusion-Dependent Vascular Ectasia: a Phase I StudyPomalidomide9Single-arm, open-labelTransfusion requirement measure2015R
NCT04167085US4NOrth American Study for the Treatment of Recurrent epIstaxis With DoxycycLine: The NOSTRIL TrialDoxycycline24Two-arm, randomized, double-blind, crossoverFrequency of epistaxis2017A
NCT02963129AR3Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHTMupirocin40Two-arm, randomized, triple-blind, placeboNosebleed by Sadick scale2017U
NCT03981562CA2Vitamin D and HHTVit D60Three-arm, randomized, double-blind, placeboChange in ESS2018R
NL2Efficacy and safety of oral itraconazole in the reduction of epistaxis severity in HHTItraconazole 25Single-arm, open-labelChange in epistaxis severity2018O
NCT03397004CA2Doxycycline for HHTDoxycycline Hyclate30Two-arm, randomized, double-blind, placebo-controlled, crossoverReduction in epistaxis (nose bleeding) severity over 96 weeks2018R
NCT04113187FR3Propranolol for Epistaxis in HHT a PatientsPropranolol38Two-arm, double-blind Cumulative duration of epistaxis (in minutes)2019NR
NCT04139018US2Timolol Gel for Epistaxis in HHTTimolol Gel30Two-arm, double-blind, randomized controlledESS2019R
NCT03910244US2Pomalidomide for the Treatment of Bleeding in HHTPomalidomide159Two-arm, placebo-controlled, double-blind Change in ESS 2019R
NCT03850730US1–2Pazopanib for the Treatment of Epistaxis in HHTPazopanib30Single-arm, open-labelPercent change in epistaxis duration in minutes2019NR
NCT03850964US2–3Pazopanib Effects on Bleeding in HHTPazopanib45 Two-arm, double-blind, placebo controlled Change in epistaxis duration in minutes2019NR
NLNAAn uncontrolled, open label pilot-study assessing the efficacy in reducing bleeding severity, and the safety of oral tacrolimus in patients with HHTTacrolimus20Uncontrolled, single-arm, open-labelChange in the epistaxis and/or gastrointestinal severity2019O
FR2Efficacy of Nintedanib per os as a treatment for epistaxis in HHT disease. A national, randomized, multicenter phase II study EPICURENintedanib60Two-arm, double-blind, randomized controlled, placeboFrequency of Epistaxis2019O
NL2Effectiveness of Somatostatin Analogues in patients with HHT and symptomatic gastrointestinal bleeding, the SAIPAN-trial: a multicenter, randomized, open-label, parallel group, superiority trialSomatostatin Analogues 38Two-arm, open-label, randomized controlledDecreasing the transfusion requirements2019O
AU2A pilot study assessing the effectiveness of oral Propranolol in preventing epistasis in patients with HHTPropranolol15Single-arm, open-label, non-randomizedChange in Epistasis2019NR
NCT03954782FR2Efficacy of Nintedanib Per os as a Treatment for Epistaxis in HHT DiseaseNintedanib60Two-arm, triple-blind, randomizedEpistaxis duration assessed on epistaxis grids completed by the patients2020O
Table 2. Compilation of the Recruiting, Ongoing, or Unknown HHT interventional clinical trials registered at the EU Clinical Trials Register (EudraCT) (, the U.S. National Library of Medicine (NCT) (, and the Australian New Zealand Clinical Trials Registry (ACTRN) ( Only interventional trials where a therapeutic drug was tested are listed. Abbreviations: Countries: AR (Argentina); AU (Australia); CA (Canada); FR (France); IT (Italy); NL (Netherlands); US (United States of America). Phase: NA (Not Applicable). Status: R (Recruiting); O (Ongoing); U (Unknown). Outcome: ESS (Epistaxis Severity Score).
Table 3. Compilation of the HHT interventional clinical trials (Completed or Terminated status).
Table 3. Compilation of the HHT interventional clinical trials (Completed or Terminated status).
Trial Registration #CountryPhaseTitleInterventionNumber of PatientsTrial DesignOutcome (Summary of Statistically Significant Outcomes)Start DateStatusLink to Results
NCT00004327US2Phase II Pilot Study of Octreotide, a Somatostatin Octapeptide Analog, for Gastrointestinal Hemorrhage in Hormone-Refractory HHT and Senile EctasiaOctreotide8Information not available-1995C-
NCT00004654US3Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for HHTSoy protein60Randomized-1996C-
NCT01031992GE3Tranexamic Acid and Epistaxis in HHTTranexamic acid23Two-arm, double-blind, controlledNo changes in hemoglobin levels. Significant reduction in ESS2002CArticle [32]
NCT00375622IL2Anti-Estrogen Therapy for HHT A Double-Blind Placebo-Controlled Clinical TrialTamoxifen25 (60) *Double-blind, placebo-controlledSignificant reduction in ESS (frequency and severity). 2005CArticle [33]
NCT00355108FR3ATERO: A Randomized Study with Tranexamic Acid in Epistaxis of Rendu Osler SyndromeTranexamic acid118 (170) *Single-arm, double-blind, randomized, crossoverSignificant decrease in the duration of epistaxis2006CArticle [34]
NCT00389935US2Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingThalidomide14Single-arm, open-label - 2006C-
NCT00588146US2Phase 2 Study of PEG-Intron in HHTPegylated IFN-α2B10Two-arm, open-label, randomizedAdverse events plus discontinuation of the study supply2007TTrial file
NCT01397695US2Topical Bevacizumab for the Management of Recurrent Epistaxis in Patients with HHTBevacizumab20Single-arm, open-label, non-randomized - 2009TTrial file
NCT01402531US2Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients with HHTBevacizumab10Single-arm, open-label, non-randomized - 2010TTrial file
EudraCT2009-018049-19AT2A randomized double-blind placebo-controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasiaBevacizumab30Two-arm, double-blind, randomizedcontrolled - 2010C-
NCT01408030US2North American Study of Epistaxis in HHT (NOSE)Bevacizumab- Estriol- Tranexamic Acid121Four-arm, double-blind, placebo-controlled, randomizedNo significant differences on epistaxis frequency2011CArticle [28]
NCT01408732US1Office-sclerotherapy for Epistaxis Due to HHTSclerotherapy with sodium tetradecyl sulfate18Two-arm, open-label, randomized-controlled No significant differences on severity of epistaxis2011CTrial file
NCT01485224IT2Efficacy of Thalidomide in the Treatment of HHTThalidomide31Single-arm, open-label, non-randomized100% showed a complete or partial response to epistaxis 2011CArticle [35]
NCT01314274AT2Intranasal Submucosal Bevacizumab for Epistaxis in HHTBevacizumab15Two-arm, double-blind, randomized, placebo-controlledNo significant differences on epistaxis frequency2011CArticle [36]
NCT01507480FR1The ELLIPSE Study: A Phase-1 Study Evaluating the Tolerance of Bevacizumab Nasal Spray to Treat Epistaxis in HHTBevacizumab42Single-arm, double-blind, randomized, placebo-controlledBevacizumab nasal spray is safe2011CArticle [37]
IT2Efficacy of thalidomide in the treatment of severe recurrent epistaxis in HHTThalidomide31Single-arm, non-controlled - 2011C-
NCT01908543UKNAIron Deficiency and HHTFerrous sulphate3Single-arm, open-label - 2013TArticle [38]
NCT01752049CANATopical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of ConceptTimolol maleate5Two-arm, double-blind, placebo-controlled - 2013C-
2013-004204-19 & NCT02157987
FR1-2Treatment of HHT of the Nasal Mucosa by Intranasal Bevacizumab: Search for Effective DoseBevacizumab30Four-arm, double-blind, randomized, controlled - 2014C-
NCT02638012CANAProspective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With HHTFloseal10Two-arm, open-label, non-randomizedNo statistically significant difference noted in ESS2015CArticle [39]
NCT02204371US & CA2Evaluation of Pazopanib on Bleeding in Subjects with HHTPazopanib7Two-arm, open-label, non-randomizedNo statistically significant difference noted in ESS2015TTrial file
2015-000385-55 & NCT02484716
FR2Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)—(TEMPO)Timolol58Two-arm, double-blind, randomizedNo statistically significant difference noted in ESS2015CArticle [40]
ES4-2A phase IV-II, single-center, open, single arm treatment, low level of intervention, to assess the efficacy clinical trial and safety of intranasal administration of ethamsylate in the treatment of HHT, during for 4 weeksEthamsylate12Single-arm, open-label, non-randomizedStatistically significant difference noted in ESS2016CArticle [31]
2016-001340-19 & NCT02874326
NL2Octreotide in Patients With GI Bleeding Due to Rendu-Osler-WeberOctreotide LAR15Single-arm, open-labelThe median number of RBC units needed decreased significantly.2016CArticle [41]
NCT03152019FR2Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT) (TACRO)Tacrolimus50Two-arm, double-blind, randomizedNo statistically significant difference noted in ESS2017CArticle [42]
Table 3. Compilation of the Completed or Terminated HHT interventional clinical trials registered at the EU Clinical Trials Register (EudraCT) (, the U.S. National Library of Medicine (NCT) ( Only interventional trials where a therapeutic drug was tested are listed. Abbreviations: Countries: AT (Austria); CA (Canada); ES (Spain); FR (France); IL (Israel); IT (Italy); NL (Netherlands); UK (United Kingdom); US (United States of America). Phase: NA (Not Applicable). Status: C (Completed) and T (Terminated). Outcome: ESS (Epistaxis Severity Score). * The Study Record Detail from the website refers to the number of patients in parenthesis.
Table 4. Orphan drugs approved by the EMA for HHT.
Table 4. Orphan drugs approved by the EMA for HHT.
Active SubstanceDateEU-Designated NumberSponsorDegree of Evidence Clinical Trial
Etamsylate11/2018EU/3/10/18/2087CSIC, SpainEudraCT: 2016–003982–24
Thalidomide02/2017EU/3/17/1845PlumeStars, S.R.L., ItalySeveral clinical trials,
Table 3
Bevacizumab12/2014EU/3/14/1390Dupuis-Girod, FranceSeveral clinical trials,
Table 3
Bazedoxifene11/2014EU/3/14/1367CSIC, SpainObservational study,
5 patients
Raloxifene06/2010EU/3/10/730CSIC, SpainObservational study,
19 patients
Back to TopTop